Watch stories about real HAEGARDA patients living the difference
*In a subgroup analysis of 24 U.S. patients receiving 60 IU/kg of HAEGARDA eligible to continue the open-label extension study for ≥12 months.
Photo does not depict actual patients.
HAEGARDA is an injectable medicine used to prevent swelling and/or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE).
In a clinical study, 40% of people on 60 IU/kg were attack free during the 16-week treatment period. In a long-term follow up study, similar responses were seen up to a maximum of 2.5 years.
Proven C1‑INH Efficacy & Established Safety Profile
HAEGARDA replaces missing or malfunctioning C1‑INH protein in HAE patients and is proven to help some achieve long‑term attack prevention
Family Planning
World Allergy Organization suggests C1‑INH as first‑line long-term prophylaxis therapy during pregnancy*
Pediatrics
Proven efficacy & established safety profile in pediatrics 6+
Starting HAEGARDA
Discover the convenience of a therapy you can administer yourself Do not attempt to self-administer unless you have been taught how by your healthcare provider
GET STARTED
Comprehensive support
Explore our patient resources from HAEGARDA ConnectSM
GET PERSONALIZED SUPPORT*It is not known if HAEGARDA can harm your unborn baby. It is not known if HAEGARDA passes into your milk and if it can harm your baby.